ClinicalTrials.Veeva

Menu

" Effect of Affordance of Objects on the Memory: Study in Transcranial Magnetic Stimulation " (SIMULANG-TMS)

C

Centre Hospitalier St Anne

Status

Unknown

Conditions

Healthy

Treatments

Other: PMv stimulation (iTBS)
Other: Control (SHAM)
Other: PMv inhibition (cTBS)

Study type

Interventional

Funder types

Other

Identifiers

NCT02956304
D15-P13

Details and patient eligibility

About

The purpose of this study is determine the involvement of motor system in the memory of manipulable objects. The idea is to stimulate the ventral premotor cortex with transcranial magnetic stimulation to see whether this stimulation will affect memory of manipulable objects.

Full description

Embodied cognition claims that representations shares processing resources with sensorimotor systems. More specifically, it has been proposed that language comprehension relies on internal simulation of the meaning. For instance, numerous studies have shown that the processing of action-related concepts involve a motor activation similar to when the action is actually performed. However, even if those studies show clearly that action-related concepts involve a motor activation, such activations may be incidental to the activation of their representations, rather than part of it. Another way to show that this motor component takes part in the representation of manipulable objetcs is to investigate whether an impairment of motor system would impair the memory of manipulable object. In this study, investigators will use Transcranial Magnetic Stimulation (TMS) to stimulate ventral premotor cortex (PMv) to see whether this stimulation will affect memory of manipulable objects, but not memory of nonmanipulable objects. For this purpose, three TMS conditions will be assessed: cTBS to inhibit the motor cortex, iTBS to excite the motor cortex, and a SHAM condition as control.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18 and 35 years
  • Right-handers (score between 70 and 100 on the scale of Edinburgh)
  • Native language : French
  • Not depressed (score lower than 14 in the BDI)
  • health insurance
  • Consent

Exclusion criteria

  • Psychiatric family history up to the second degree
  • Medical treatment, in particular psychotropic being able to affect the memory and the attention
  • view or hearing disorders (not compensated)
  • neurological histories (epilepsy, alcoholism in particular) or psychiatric or important memory complaints
  • Contraindications for the SMT
  • contraindications in the MRI

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

30 participants in 6 patient groups

Group iTBS-cTBS-SHAM
Other group
Description:
PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)
Group iTBS-SHAM-cTBS
Other group
Description:
PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)
Group cTBS-iTBS-SHAM
Other group
Description:
PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)
Group cTBS-SHAM-iTBS
Other group
Description:
PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)
Group SHAM-iTBS-cTBS
Other group
Description:
control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)
Group SHAM-cTBS-iTBS
Other group
Description:
control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
Treatment:
Other: Control (SHAM)
Other: PMv stimulation (iTBS)
Other: PMv inhibition (cTBS)

Trial contacts and locations

1

Loading...

Central trial contact

Benoit CREPON, MD; Marie GODARD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems